Michael Gelband’s BioNTech BNTX Stock Holding History

Michael Gelband’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-14,740	Closed	-$1.59M	–	1717
2023 Q2	$1.59M	Buy	+14,740	New	+$1.66M	0.01%	903
2023 Q1	–	Sell	-51,782	Closed	-$7.78M	–	1770
2022 Q4	$7.78M	Buy	+51,782	New	+$7.97M	0.11%	232
2022 Q2	–	Sell	-5,164	Closed	-$881K	–	1967
2022 Q1	$881K	Buy	+5,164	New	+$868K	0.01%	1233
2021 Q4	–	Sell	-5,846	Closed	-$1.6M	–	2182
2021 Q3	$1.6M	Buy	5,846 +2,206	+61%	+$701K	0.02%	814
2021 Q2	$815K	Buy	3,640 +1,533	+73%	+$289K	0.01%	1099
2021 Q1	$230K	Buy	+2,107	New	+$224K	﹤0.01%	1817
2020 Q4	–	Sell	-10,860	Closed	-$752K	–	1978
2020 Q3	$752K	Buy	+10,860	New	+$779K	0.02%	805

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.72B AUM 7.92% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Michael Gelband's BNTX Position: Q3 2023 in Review

Michael Gelband sold out of BioNTech (BNTX) in Q3 2023, closing a stake of 14,740 shares — an estimated $1.59M sold.

Michael Gelband first reported a position in BNTX in Q3 2020 and held it in 7 quarters. The position peaked at $7.78M in Q4 2022. 252 funds tracked by Wall St. Rank hold BNTX as of Q3 2023.

Michael Gelband reported no remaining BioNTech position as of Q3 2023 after selling out during the quarter.
Michael Gelband sold 14,740 BioNTech shares in Q3 2023, an estimated $1.59M.
Michael Gelband first reported a position in BioNTech in Q3 2020 and held it in 7 quarters.
Michael Gelband's BioNTech position peaked at $7.78M in Q4 2022.
252 funds tracked by Wall St. Rank held BioNTech as of Q3 2023.

Based on ExodusPoint Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.